Now, Libtayo (cemiplimab) is also in the mix. Sanofi and Regeneron have just halted a 466-patient phase 3 trial of the drug in combination with chemo rarely, saying they saw a significant ...

Moments after Regeneron CEO Len Schleifer scolded analysts ... pointed to positive data posted for adjuvant use of Libtayo in patients with cutaneous squamous cell carcinoma (CSCC).

While Regeneron does not break down sales in LIBTAYO to its corresponding number of patients, we can make some rough estimates to gauge the extent of the new market. To make our estimate ...

Patients were of a median age of 51 years old – 78% with SCC and 22% with adenocarcinoma or adenosquamous carcinoma – and randomised to receive 350mg Libtayo every three weeks or chemotherapy ...

Regeneron stock jumped Tuesday after the biotech giant topped Wall Street's December-quarter calls on the back of its cancer drug Libtayo. The company also announced a dividend for the first time.

Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab ... This open-label multi-centre randomised trial included patients with disease ...

Immuneering (IMRX) announced a clinical supply agreement with Regeneron Pharmaceuticals (REGN) for its anti-PD-1 therapy, Libtayo. The supply ...

The supply agreement supports the evaluation of Immuneering’s lead product candidate, IMM-1-104, in combination with Libtayo in patients with ... with IMM-1-104. Regeneron is a global leader ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo ® (cemiplimab ... and cemiplimab could offer a new standard of care for patients in Scotland who ...